Zentalis Q2 cash $553M; azenosertib ORR 36.8% with RP2D set

Zentalis Pharmaceuticals, Inc.

2023-Q2 EPS reported -$2.93

Cash, equivalents and marketable securities $553.0M as of June 30, 2023; runway into 2026.
Azenosertib monotherapy ORR 36.8% in ovarian cancer/USC; RP2D set at 400 mg QD 5:2.
Phase 1b azenosertib + paclitaxel ORR 50.0% (mPFS 7.4 mo); + carboplatin ORR 35.7% (mPFS 10.4 mo).
Q2 R&D expense $42.7M, G&A $15.7M; one-time Zentera termination charge $45.6M.
Closed $250M public offering (11.03M shares at $22.66) in June; appointed CSO Kimberly Freeman.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Zentalis Pharmaceuticals, Inc. reported financial results for the quarter ended June 30, 2023.

Period: the quarter ended June 30, 2023
Result: reported results

Exact text from the filing

Zentalis Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2023

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Zentalis Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001725160-23-000154

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.